+ Translate

Evaluation of a new bronchodilator, Formoterol, using biochemical parameters

, : Evaluation of a new bronchodilator, Formoterol, using biochemical parameters. International Journal of Clinical Pharmacology, Therapy, and Toxicology 23(9): 461-468

The authors administered orally 40, 60 and 80 micrograms of Formoterol which was developed as a new bronchodilator and 4 mg of Salbutamol which is considered to be a beta 2-selective drug, to healthy adults. Pulse rate, blood pressure and blood levels of cyclic GMP, free fatty acid, cyclic AMP, glucose and lactic acid were measured in order to evaluate efficacy and dosage of Formoterol and to compare efficacy of this drug with that of Salbutamol. As a result, it is considered that Formoterol has a strong dose dependent beta 2-effect with 40 micrograms of Formoterol almost as high as 4 mg of Salbutamol in beta 2-effect. In addition, Formoterol has almost no alpha-effect and its beta 1-effect can be considered negligible in the doses of 60 micrograms and 80 micrograms.

(PDF 0-2 workdays service)

Accession: 005395348

PMID: 2997046

Submit PDF Full Text: Here

Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:

Related references

Cazzola, M.; Matera, M.Gabriella.; D'Amato, M.; Califano, C.; Sanduzzi, A.; Vatrella, A.; D'Amato, G., 2003: Bronchodilator response to formoterol Turbuhaler in patients with COPD under regular treatment with formoterol Turbuhaler. Formoterol Turbuhaler has been suggested for as-needed use in asthmatic patients. We investigated whether regular treatment with formoterol would modify the dose-response curves to formoterol in patients with partially reversible COPD. In this ran...

Cazzola, M.; Noschese, P.; Salzillo, A.; D.G.glio, C.; D'Amato, G.; Matera, M.Gabriella., 2005: Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients. We conducted a randomized, crossover trial with tiotropium 18 microg once daily (group A), and formoterol 12 microg twice daily (group B) over a 5-day period for each drug, with a 10-day washout, in 20 COPD patients. At the end of each period, pat...

Anderson, G.P., 1991: Pharmacology of formoterol: an innovative bronchodilator. Formoterol is an innovative, highly potent, beta-2 selective adrenoceptor agonist combining the clinical advantages of rapid onset of action with a duration of action in excess of 12 h. In vitro, formoterol is a potent airway smooth muscle relaxan...

Arvidsson, P.; Larsson, S.; Löfdahl, C.G.; Melander, B.; Wåhlander, L.; Svedmyr, N., 1989: Formoterol, a new long-acting bronchodilator for inhalation. The aim of this study was to evaluate if treatment with inhaled formoterol is appreciated by asthmatics and whether it causes tachyphylaxis. Twenty stable asthmatics were included in a randomized, double-blind, crossover study. They were treated f...

Barcelo, J.M.; Miranda, A.; Segurado, E.; Munoz, C.; Munoz, M.; Vega, J.M.; Carmona, M.J.; Alonso, L., 1996: Comparison of the bronchodilator effect of terbutaline and formoterol. Allergy (Copenhagen) 51(SUPPL 31): 56

Maesen, F.P.; Smeets, J.J.; Gubbelmans, H.L.; Zweers, P.G., 1990: Bronchodilator effect of inhaled formoterol vs salbutamol over 12 hours. The bronchodilator effects were compared in 16 stable asthma patients for 12 hours after either 12 micrograms formoterol or 200 micrograms salbutamol from a metered-dose aerosol in a randomized, double-blind, crossover study. The FEV1 measured bef...

Beier, J.; Beeh, K-M.; Brookman, L.; Peachey, G.; Hmissi, A.; Pascoe, S., 2010: Bronchodilator effects of indacaterol and formoterol in patients with COPD. Resting inspiratory capacity (IC) reflects static hyperinflation in chronic obstructive pulmonary disease (COPD). This study compared the effects of formoterol and indacaterol, a novel once-daily ultra-long-acting beta(2)-agonist (or ultra-LABA),...

Sasaki, H.; Kamimura, H.; Shiobara, Y.; Esumi, Y.; Takaichi, M.; Yokoshima, T., 1982: Disposition and metabolism of formoterol fumarate, a new bronchodilator, in rats and dogs. 1. The disposition and metabolism of formoterol fumarate, a highly potent beta 2-adrenoceptor stimulant, were studied in rats and dogs. 2. After oral administration of [3H] formoterol fumarate to dogs, unchanged formoterol accounted for greater th...

Sayiner, A.; Cimrin, A.H.; Ersoy, M.S.; Pacaci, E.; Ozturk, A.; Group, T.F.rmoterol Study, 1997: Bronchodilator activity of single-dose formoterol in asthmatic patients. European Respiratory Journal Supplement 10(25): 242S, Sept

Masoli, M.; Williams, M.; Weatherall, M.; Beasley, R., 2005: The 24 h duration of bronchodilator action of the budesonide/formoterol combination inhaler. The duration of bronchodilator action of the long-acting beta-agonist formoterol when administered in the evening has not been investigated. In this study we have investigated whether a single evening dose of formoterol, administered from the comb...